Contact Us
Wolfe Laboratories is now a subsidiary of Pace Analytical Life Sciences

Press Releases

Celebrating a Decade of Success – Wolfe Laboratories’ 2009 Biopharma Conference and Ten Year Anniversary

BOSTON, MA – (BUSINESS WIRE) – April 9, 2009 – Wolfe Laboratories, Inc. (WLI), built with the goal of helping biopharmaceutical companies develop innovative new drugs, recently celebrated its tenth anniversary of providing outsourced early stage pharmaceutical development services. Ten years ago, Dr. Janet Wolfe, President and Founder of WLI, recognized the abundance of innovation that the Boson ecosystem spawned through its world class academic institutions, experienced venture capitalists and its burgeoning entrepreneurial community, and she foresaw a high demand for experienced pharmaceutical development services. To capitalize on her insight, Wolfe rented a 2,000 square foot facility in Newton, MA and formed WLI.


In celebration of this milestone, Wolfe Laboratories partnered with the United Way to host the 2009 Wolfe Biopharma ConferenceFilling Biopharma’s Pipeline, held on April 2nd, 2009 at the Mandarin OrientalHotel in Boston. This conference raised money for United Way’s Math, Science and Technology initiative(MSTi) and other youth programs. Over the past decade, Wolfe Laboratories has repeatedly invested in youth and given back to the life sciences community. During site visits with children involved in the United Way’s MSTi after-school program, WLI’s scientists conducted hands-on experiments to encourage underserved children to pursue careers in science. Wolfe Laboratories has facilitated career development for high school and college students through its internship and co-op programs. By partnering with several universities in Boston, WLI has provided undergraduate and graduate students with the opportunity to gain valuable work experience through highly interactive job training. The company has also supported The American Cancer SocietyAlzheimer’s AssociationCystic Fibrosis Foundation, and The Jimmy Fund.


The 2009 Wolfe Biopharma Conference: Filling Biopharma’s Pipeline featured industry leaders in biopharma, academia, venture capital, and media who discussed the existing trends and challenges in the biopharma ecosystem. Dr. Wolfe kicked off the conference by giving a perspective on some of the forces that are influencing the pipeline’s future outlook, among them a severely weakened economy, the patent cliff, mega-mergers, reduced resources for biotechs that develop the majority of new compounds, and a deployment of resources towards later-stage assets. At the same time, she maintained a positive outlook for the industry, “Companies who are currently focusing on late stage discovery and early stage development will find themselves in a seller’s market in a couple of years.” Following Wolfe’s enlightening introduction, Ronald Borchardt, Ph.D., the Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry, University of Kansas gave the keynote address. Other expert speakers included Kazumi Shiosaki, Ph.D., Managing Director, MPM Capital; Patricia Hurter, Ph.D., Vice President, Pharmaceutical Development, Vertex Pharmaceuticals; Dhiren Thakker, Ph.D., Associate Dean for Research and Graduate Education, Ferguson Distinguished Professor of Molecular Pharmaceutics,University of North Carolina; Rosina Maar Pavia, M.D., M.B.A., Partner, Pappas Ventures; and Michael Powell, Ph.D., General Partner, Sofinnova Ventures.


Following the speaker presentations, a plenary discussion included Mark Fishman, M.D., President, Novartis Institutes for BioMedical Research; Steven Ainsley, Publisher, The Boston Globe; Shirley Leung, Managing Editor of Business News, The Boston Globe; Charles Kravetz, President, New England Cable News; and Michael Durkin, CEO, United Way. Discussing future industry challenges and what it takes to succeed in the competitive marketplace, one important theme repeatedly emerged – the need for insight and innovation. Mark Fishman set the stage, “Technology by itself never changes science. The future is not determined by our technology, the future is determined by insights. Galileo was not the first one to invent the telescope, he was the first one who thought of using it to look at Jupiter. So it’s insight; it’s not the technology per se.” Wolfe Laboratories’ successful ten year anniversary is one more benchmark added to its long list of achievements thus far:


  • 2000, WLI celebrated its first year of profitability
  • 2002, WLI received its first major contract of $250,000 for a cardiology drug
  • 2004, WLI relocated to a 11,000 square foot facility in Watertown
  • 2005, WLI experienced 100% revenue growth
  • 2007, WLI tripled its lab space in a 21,000 square foot facility
  • 2008, Dr. Wolfe was named Boston’s Entrepreneur of the Year by the Greater Boston Chamber of Commerce
  • Since 2006, over forty clients advanced programs through clinical trials and over a dozen were acquired by big pharma


Wolfe Laboratories never stops looking to the future and preparing for the next big step. The team is constantly seeking ways to bring increased value to clients by providing comprehensive early stage drug development programs that will improve their likelihood of success.


About Wolfe Laboratories, Inc. (WLI)

WLI is a pharmaceutical development company that offers comprehensive IND-enabling programs for biologics and small molecules. Through its customized development services in ADMET and CMC areas, as well as GLP and cGMP testing, the company brings value to its clients by rapidly providing high quality project planning and execution through its experienced staff and management team. Drug Development Done Right. On Time. For more information, visit